Pharmacological effects Clinical application Side effects Precautions Chemical Properties Uses Production method
ChemicalBook > CAS DataBase List > Cilostazol

Cilostazol

Pharmacological effects Clinical application Side effects Precautions Chemical Properties Uses Production method
Product Name
Cilostazol
CAS No.
73963-72-1
Chemical Name
Cilostazol
Synonyms
RETAL;OPC 21;PLETAL;PLETAAL;Cilostal;Cilostazo;OPC 13013;CILASTAZOL;CILOSTAZOL;CILOSTAZOLE
CBNumber
CB2362876
Molecular Formula
C20H27N5O2
Formula Weight
369.46
MOL File
73963-72-1.mol
More
Less

Cilostazol Property

Melting point:
159-160°C
Boiling point:
499.57°C (rough estimate)
Density 
1.1832 (rough estimate)
refractive index 
1.7600 (estimate)
storage temp. 
Inert atmosphere,Room Temperature
solubility 
DMSO: 18 mg/mL, soluble
form 
solid
pka
14.22±0.20(Predicted)
color 
off-white
λmax
257nm(MeOH)(lit.)
Merck 
14,2277
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months
InChIKey
RRGUKTPIGVIEKM-UHFFFAOYSA-N
More
Less

Safety

Hazard Codes 
Xi
WGK Germany 
2
RTECS 
VC8277500
HS Code 
29339900
Hazardous Substances Data
73963-72-1(Hazardous Substances Data)
Toxicity
LD50 in mice, rats (mg/kg): >2000, >2000 i.p.; >5000, >5000 orally (Nomura)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P308+P313IF exposed or concerned: Get medical advice/attention.

P405Store locked up.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
C0737
Product name
Cilostazol
Purity
≥98% (HPLC), powder
Packaging
10mg
Price
$212
Updated
2024/03/01
Sigma-Aldrich
Product number
1134153
Product name
Cilostazol
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
200mg
Price
$1090
Updated
2024/03/01
TCI Chemical
Product number
C2587
Product name
Cilostazol
Purity
>98.0%(HPLC)
Packaging
1g
Price
$105
Updated
2024/03/01
TCI Chemical
Product number
C2587
Product name
Cilostazol
Purity
>98.0%(HPLC)
Packaging
5g
Price
$355
Updated
2024/03/01
Alfa Aesar
Product number
J62301
Product name
Cilostazol, 98%
Packaging
10mg
Price
$120.65
Updated
2024/03/01
More
Less

Cilostazol Chemical Properties,Usage,Production

Pharmacological effects

Cilostazol is commonly used clinically anti-platelet and anti-clotting drugs. It belongs to a phosphodiesterase inhibitor and can inhibit the activity of phosphodiesterase of platelet and smooth muscle cells, leading to increase of the cAMP concentration in platelets and vascular smooth muscle. It can significantly inhibit the platelet aggregation induced by various kinds of aggregation inducers, and can cause the dissociation of the aggregates. Its major metabolite, epoxide has a three to four fold activity of the prototype drug. It has significant antithrombotic effect on the brain circulation and peripheral circulatory disturbance caused by collagen, ADP, arachidonic acid and sodium laurate. Artery injection of this product can increase the blood flow rate with the strongest effect on the peripheral blood vessels but the weakest effect on the cerebral blood vessels.
This product is rapidly absorbed in the intestine after oral administration with the Tmax being 3h, PPB being about 95%. Consecutive administration of four days by twice per day caused no increase in the plasma concentration accumulation. It has good tissue distribution with especially high level in the stomach, liver and kidney. At 72h after administration, 42.75% of the administered drug is excreted via urine and 61.7% is subject to fecal excretion. After 48 hour of administration, bile excretion rate is 31.7%. T1/2α is 2.2h and T1/2β is 18h.

Clinical application

It can be used to alleviate the ischemic symptom such as ulcers, limb pain, cold sensation and intermittent claudication caused by chronic arterial occlusive disease. It can also be applied to the adjuvant treatment of atherosclerosis, arteritis, thromboangiitis obliterans, diabetes-induced ischemia of extremity and takayasu arteritis. Cilostazol also be used as a complementary therapy after surgical treatment to help alleviate the symptoms, improve the circulation and inhibiting thrombosis in transplanted blood vessel.

Side effects

There may be occasionally rash, hives, itching, palpitations, pulse frequency, low blood pressure, fever, dizziness, dizziness, vertigo, insomnia or drowsiness, swelling, pain, fatigue, weakness, stomach discomfort, nausea, vomiting, loss of appetite, diarrhea, upper abdominal pain, abdominal fullness, increased level of GOT (serum alanine aminotransferase), ALP (serum alkaline phosphatase), LDH (serum lactate dehydrogenase), BUN (blood urea nitrogen), creatinine and uric acid, gastrointestinal bleeding, epistaxis, subcutaneous bleeding, retinal hemorrhage, hematuria, bleeding tendencies and thrombocytopenia.
The above information is edited by the chemicalbook of Dai Xiongfeng.

Precautions

Patients of hemophilia, capillary fragility syndrome, upper gastrointestinal bleeding and urinary tract bleeding as well as vitreous hemorrhage should be disabled. Women of pregnancy or possible pregnancy should be disabled.
This product is should be taken cautious when being applied to patients in the use of anticoagulants (warfarin) or antiplatelet drugs (aspirin, Ticlid) patients. When using cilostazol, the patients should be subject to blood coagulation performance test.
Women in menstrual period, patients of bleeding tendency or with severe hepatic and renal dysfunction as well as elderly should administer with caution; breast-feeding women should avoid breast-feeding.

Chemical Properties

It is colorless, needle-like crystals obtained from methanol with the m.p. being 159.4~160.3 ℃ and the UV absorption maximum (methanol) being 257nm (ε15200). It is easily soluble in acetic acid, chloroform, N-methyl-2-pyrrolidone or dimethyl sulfoxide and almost insoluble in ether, water, 0.1mol/L hydrochloric acid or 0.1mol/L sodium hydroxide.

Uses

It can significantly inhibit the platelet aggregation caused by various inducers and aggregates and can dissociate the aggregates without causing secondary aggregation. It has significant antithrombotic effect on the brain circulation and peripheral circulatory disturbance caused by collagen, ADP, arachidonic acid and sodium laurate. It can also be used for treating ischemic diseases such as chronic arterial occlusive ulcer, pain and coldness.

Production method

Take 5-chloro-N-cyclohexyl pentanamide as the raw material. Under ice-cooling, to 15 mL of benzene solution containing 1.75g ​​5-chloro-N-cyclohexyl-pentyl amide solution, slowly add 1.9 g of phosphorus pentachloride and stir at room temperature for 1h. At room temperature and stirring, add 1.4mol/L HN3 to 1 mL of the benzene solution. After stirring overnight, continue the reflux for 2h. The solvent was distilled off under reduced pressure with the residue being poured into ice water and subject to chloroform extraction. The extract was successively washed with water, dilute sodium bicarbonate solution and water, further dried by anhydrous sodium sulfate. After the chloroform was distilled off, the residue was subject to isopropanol-water recrystallization to obtain 1.7 g of 5-(4-chlorobutyl)-l-cyclohexyl-tetrazole, being as colorless needle-like crystals with the yield being 87% and the m.p. being 48-49 ℃.
Dissolve 3.2 g 6-hydroxy-3, 4-dihydrogen-2(1H)-quinolinone and 1.4 g of potassium hydroxide in 20 mL of isopropanol. Under reflux, add drop wise of the isopropanol solution containing 5.7 g of the tetrazole obtained above. Continue stirring and reflux for 4h. Evaporate to dryness with the residue being extracted with chloroform. The extract was washed with l mol/L sodium hydroxide solution, dilute hydrochloric acid and water, dried by anhydrous sodium sulfate. Chloroform was distilled off with the residual liquid being subject to chromatograph on silica gel. Use chloroform-methanol (30: 1) for elution. Then apply methanol-water recrystallization to obtain 6.0 g of colorless needles cilostazol with the yield being 74% and the melting point being 158 ​​~ 159 ℃.

Description

Cilostazol is a platelet aggregation inhibitor with cerebral vasodilating activity, indicated for use in stroke and myocardial infarction. In patients with cerebral thrombosis, transient ischemia and cerebral arteriosclerosis, cilostazol significantly inhibits ADP-, collagenand epinephrine-induced platelet aggregation. Side effects include headache and tachycardia.

Chemical Properties

Colourless Needles

Originator

Otsuka (Japan)

Uses

A potent phosphodiesterase III A (PDE3A) inhibitor (IC50=0.2uM) and inhibitor of adenosine uptake. Has antimitogeni, antithrombotic, vasodilatory and cardiotonic properties in vivo. Also affects lipid levels in vivo

Uses

antibacterial; LD50(iv) 280mg/kg(mouse)

Uses

An inhibitor of phosphodiesterase III

Definition

ChEBI: A lactam that is 3,4-dihydroquinolin-2(1H)-one in which the hydrogen at position 6 is substiuted by a 4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy group.

brand name

Pletal (Otsuka);Reta.

General Description

Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent.

Biological Activity

Potent phosphodiesterase III A (PDE3A) inhibitor (IC 50 = 0.2 μ M) and inhibitor of adenosine uptake. Has antimitogenic, antithrombotic, vasodilatory and cardiotonic properties in vivo . Also affects lipid levels in vivo .

Mechanism of action

Cilostazol exhibits greater selectivity than dipyridamole as an inhibitor of PDE3A. The drug does not affect the other PDEs (PDEs 1, 2, or 4). Cilostazol reversibly inhibit platelet aggregation induced by a number of stimuli, such as thrombin, ADP, collagen, or stress from exercise. Additionally, cilostazol inhibits adenosine uptake, leading to increased activity of adenosine at A1 and A2 receptors.

Clinical Use

Cilostazol, a quinolinone derivative, is a potent orally active antiplatelet drug approved for the treatment of intermittent claudication (a peripheral artery disease resulting from blockage of blood vessels in the limbs).

Drug interactions

Potentially hazardous interactions with other drugs
Anagrelide: avoid concomitant use. Antibacterials: concentration increased by clarithromycin and erythromycin - consider reducing cilostazol dose.
Antifungals: concentration possibly increased by ketoconazole and itraconazole - consider reducing cilostazol dose.
Antivirals: concentration possibly increased by boceprevir, ritonavir and telaprevir - reduce cilostazol dose to 50 mg twice daily.
Calcium-channel blockers: concentration increased by diltiazem - consider reducing cilostazol dose.
Ulcer-healing drugs: concentration increased by omeprazole - consider reducing cilostazol dose.

Metabolism

Cilostazol is rapidly absorbed after oral administration, particularly with a high-fat meal, which greatly increases its bioavailability to approximately 90%. It is extensively metabolized in the liver by various cytochromes. The most important cytochromes appear to be CYP3A4 and, to lesser extent, by CYP2C19, with an elimination half-life of approximately 11 to 13 hours. Among the various metabolites produced (11 metabolites are known), the two major metabolites are 3,4-dehydrocilostazol and 4′-trans-hydroxycliostazol. These two metabolites are pharmacologically active. Studies indicate that the concomitant administration of cilostazol with CYP3A inhibitors can greatly increase cilostazol blood concentrations, and a dose reduction may be required. Similar results are seen when CYP2C19 is inhibited, leading to decreased formation of 4-trans-hydroxycliostazol and significant increases in cilostazol and 3,4-dehydrocilostazol.

storage

Store at RT

References

1) Schror (2002) The pharmacology of cilostazol; Diabetes Obes. Metab., 4 S14

Cilostazol Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Cilostazol Suppliers

Shenzhen Neptunus Pharmaceutical Co., Ltd.
Tel
0755-26968666
Fax
0755-2680892
Country
China
ProdList
15
Advantage
60
Hefei Ruiluo New Material Technology Co., Ltd.
Tel
19567218739
Email
1759672789@qq.com
Country
China
ProdList
1484
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
4006608290; 18621169109
Fax
86-21-61259102
Email
market03@meryer.com
Country
China
ProdList
40241
Advantage
62
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Fax
86-21-50328109
Email
3bsc@sina.com
Country
China
ProdList
15848
Advantage
69
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Fax
021-67121385
Email
Sales-CN@TCIchemicals.com
Country
China
ProdList
24539
Advantage
81
Energy Chemical
Tel
021-021-58432009 400-005-6266
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
44751
Advantage
61
Capot Chemical Co., Ltd
Tel
+86 (0) 571 85 58 67 18
Fax
0086-571-85864795
Email
sales@capotchem.com
Country
China
ProdList
18217
Advantage
66
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Fax
021-64823266
Email
zhangsn@titansci.com
Country
China
ProdList
14113
Advantage
59
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696;
Email
info@hanhongsci.com
Country
China
ProdList
42982
Advantage
64
Chemsky(shanghai)International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32344
Advantage
50
XiaoGan ShenYuan ChemPharm co,ltd
Tel
0712-0712-2580635 15527768850
Email
1791901229@qq.com
Country
China
ProdList
8849
Advantage
52
Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Fax
86-21-63290778 86-21-63218885
Email
sj_scrc@sinopharm.com
Country
China
ProdList
9823
Advantage
79
Shanghai Sunway Pharmaceutical Technology Co., Ltd
Tel
+8618575662672 18575662672
Fax
021 51613951
Email
mzeng@3wpharm.com
Country
China
ProdList
9747
Advantage
57
Hunan Hui Bai Shi Biotechnology Co., Ltd.
Tel
0731-85526065 13308475853
Email
ivy@hnhbsj.com
Country
China
ProdList
4550
Advantage
62
Wuhan Fortuna Chemical Co., Ltd
Tel
027-027-59207852 13308628970
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2893
Advantage
58
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4647
Advantage
58
ShangHai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847 13636370518
Fax
021-55068248
Email
shyysw007@163.com
Country
China
ProdList
4941
Advantage
60
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Tel
0755-83725681-603
Fax
+86 755 28094224
Country
China
ProdList
4505
Advantage
50
Shanghai civi chemical technology co.,Ltd
Tel
86-21-34053660
Fax
86-21-34053661
Email
sale@labgogo.com
Country
China
ProdList
9872
Advantage
52
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12338
Advantage
58
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1494
Advantage
55
Shanghai T&W Pharmaceutical Co., Ltd.
Tel
+86 21 61551611
Fax
+86 21 50676805
Country
China
ProdList
9901
Advantage
58
Shanghai Jian Chao Chemical Technology Co., Ltd.
Tel
021-50430803 18017383231
Fax
qq:2817624287
Email
983544897@qq.com
Country
China
ProdList
9352
Advantage
55
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7553
Advantage
61
9ding chemical ( Shanghai) Limited
Tel
4009209199
Fax
86-021-52271987
Email
sales@9dingchem.com
Country
China
ProdList
22519
Advantage
55
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
18521735133 18521732826;
Fax
021-50323701
Email
market@aladdin-e.com
Country
China
ProdList
25015
Advantage
65
The future of Shanghai Industrial Co., Ltd.
Tel
021-61552785
Fax
021-55660885
Email
sales@shshiji.com
Country
China
ProdList
9552
Advantage
55
Hunan Furui Biopharma Technology Co., Ltd.
Tel
15902102743
Fax
0731-57805668
Email
shelley@furuipharma.com
Country
China
ProdList
435
Advantage
55
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Fax
020-39119999
Email
isunpharm@qq.com
Country
China
ProdList
4428
Advantage
55
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3750
Advantage
55
TargetMol Chemicals Inc.
Tel
021-33632979 15002134094
Fax
021-33632979
Email
marketing@targetmol.com
Country
China
ProdList
7934
Advantage
58
Shanghai Huikai Chemical Technology Co., Ltd.
Tel
021-61995394 18916691159
Email
chemicalsea@163.com
Country
China
ProdList
1975
Advantage
58
Wuhan DKY Technology Co.,Ltd.
Tel
27-81302488 18007166089
Fax
027-81302088
Email
info@dkybpc.com
Country
China
ProdList
2024
Advantage
58
Eastbang Pharmaceuticals Technology Co., Ltd.
Tel
+86 (20) 28996708,29078958,28139708,29076128,28133708,28139728,28139738,28133718,021-31663278,021-31663578,021-60538387
Fax
+86 (20) 39218032
Country
China
ProdList
454
Advantage
58
Bide Pharmatech Ltd.
Tel
400-1647117 15221909166
Fax
+86-21-61629029
Email
product02@bidepharm.com
Country
China
ProdList
41438
Advantage
60
Shanghai DiBai Chemicals Co., Ltd.
Tel
021-54359730 400-008-9730
Fax
021-54353864
Email
info@chemxyz.com
Country
China
ProdList
3993
Advantage
60
ChemStrong Scientific Co.,Ltd
Tel
0755-0755-66853366 13670046396
Fax
0755-28363542
Email
sales@chem-strong.com
Country
China
ProdList
17982
Advantage
56
Beijing FYF Chemicals Co., Ltd
Tel
010-61647239; 15318973357
Fax
010-57903446
Email
1460285141@qq.com
Country
China
ProdList
2948
Advantage
58
Shanghai CanSpecsci Instrument Co., Ltd.
Tel
400-6087598 15021221957
Fax
4006087598-8012
Email
order@canspecsci.com
Country
China
ProdList
2071
Advantage
56
Wuhan Dahua Pharmaceutical Co., Ltd.
Tel
027-59262863 13277907145 3091977954
Fax
027-59420980
Country
China
ProdList
4951
Advantage
58
Wuhan Dahua Weiye Pharmaceutical Chemical Co., Ltd.
Tel
027-59420981,18702770802
Fax
027-83322098
Country
China
ProdList
1975
Advantage
50
Lihe Wuhan New Chemical Materials Co., Ltd.
Tel
027-88395709
Fax
027-88391805
Country
China
ProdList
430
Advantage
50
Shanghai Song Yuan Chemical Technology Co., Ltd.
Tel
010-1234567 18521000990
Fax
86-021-33275113
Email
sonyuanchemical@163.com
Country
China
ProdList
6490
Advantage
50
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Fax
025-68650336
Email
info@adooq.cn
Country
China
ProdList
2989
Advantage
60
Credit Asia Chemical Co., Ltd.
Tel
+86 (21) 61124340
Fax
+86 (21) 6129-4103
Country
China
ProdList
9767
Advantage
58
Hubei Jusheng Technology Co.,Ltd
Tel
027-59599241 18871490274
Fax
027-59599241
Email
1400878000@qq.com
Country
China
ProdList
9972
Advantage
58
LETOPHARM LIMITED
Tel
+86-21-5821 5861
Fax
+86-21-5106 2861
Email
sales@letopharm.com
Country
China
ProdList
2384
Advantage
58
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Fax
-
Email
xg01_gj@163.com
Country
China
ProdList
9503
Advantage
50
Guangzhou Ciming Biological Technology Co., Ltd.
Tel
020-38082199,29065168,38082986,29878298,29866629,4000192398
Fax
+86 (20)38082986
Country
China
ProdList
831
Advantage
60
More
Less

View Lastest Price from Cilostazol manufacturers

WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
Product
Cilostazol 73963-72-1
Price
US $0.00/KG
Min. Order
100g
Purity
98%+
Supply Ability
100kg
Release date
2020-11-24
Shanghai Affida new material science and technology center
Product
Cilostazol 73963-72-1
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99
Supply Ability
50000KG/month
Release date
2024-03-13
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Cilostazol 73963-72-1
Price
US $0.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
800kg/month
Release date
2021-06-15

73963-72-1, CilostazolRelated Search:


  • 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE
  • 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1h)-quinolinone additional name: 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4- tetrahydro-2-oxoquinolinone
  • OPC-13013, Pletal, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
  • 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
  • CILOSTAZOL JP
  • 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE(CILOSTAZOL)
  • OPC 13013, OPC 21, Pletaal, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
  • 6-[4-(1-Cyclohexyl-1H-tetrazol-5-y1)butoxy]-3,4-dihydrcr2(1H)-quinolinone
  • 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolone
  • Cilostazol (200 mg)
  • Cilostazol, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-2-oxo-1,2,3,4-tetrahydroquinoline
  • 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy]-1,2,3,4-tetrahydroquinolin-2-one
  • Cilostazol(Micronized
  • 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)quinoline-2,3(1H,4H)-dione
  • 2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-
  • Cilostazo
  • CILASTAZOL
  • CILOSTAZOL
  • CILOSTAZOLE
  • RETAL
  • OPC 13013
  • OPC 21
  • PLETAL
  • PLETAAL
  • 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4-tetrahydro-2-oxoquinolinone
  • Cilostal
  • CILOSTAZOL INTERMEDIATES
  • N-cyclohexyl-5-(4-chlorobutyl)tetrazol
  • CilostazolC20H27N502
  • 6-[4-(1-cyclohexyl -1H-tetrazole -5-sulfuryl )butoxy ]-3,4-dihydro -2(1H)-quinolone
  • THE INTERMEDIATE OF CILOSTAZOL(N-CYCLOHEXYL-5-(4-CHLOROBUTYL)TETRAZOL)
  • 3,4-dihydro-6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-2(1h)-quinolinon
  • 3,4-dihydro-6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-2(1h)-quinolinone
  • 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-3,4-dihydro-1H-quinolin-2-one
  • Cilostazol &gt
  • Cilostazol Cilostazol
  • Cilostazol RS
  • Cilostazol USP/EP/BP
  • Cilostazol (OPC-13013
  • CilostazolQ: What is Cilostazol Q: What is the CAS Number of Cilostazol Q: What is the storage condition of Cilostazol Q: What are the applications of Cilostazol
  • Cilostazol (1134153)
  • Cilostazol IP/USP
  • ciloprost impurities
  • Cilostazol, ≥ 98.0%
  • 73963-72-1
  • 73693-72-1
  • 76963-72-1
  • C20H27N5O2
  • C20H27O2N5
  • Cell Signaling and Neuroscience
  • Cell Biology
  • BioChemical
  • Cyclic Nucleotide Metabolism
  • G Proteins and Cyclic Nucleotides
  • Phosphodiesterase Inhibitors
  • inhibitor
  • Cardiovascular APIs
  • API's